In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Repare Therapeutics (RPTX – Research Report), with a price target of $25.00. The company’s shares closed yesterday at $3.28.
According to TipRanks, Catanzaro is a 4-star analyst with an average return of 9.1% and a 42.17% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Ocular Therapeutix, and Iovance Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Repare Therapeutics with a $16.60 average price target, which is a 406.10% upside from current levels. In a report released yesterday, Capital One Financial also maintained a Buy rating on the stock with a $21.00 price target.
The company has a one-year high of $13.85 and a one-year low of $2.98. Currently, Repare Therapeutics has an average volume of 126.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Repare Therapeutics (RPTX) Company Description:
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
